Immunocore has spent four years proving that a soluble T cell receptor can be a commercial medicine, and the AACR survival update finally closed the durability argument in metastatic uveal melanoma. The remaining debate is whether that same molecule, and the broader ImmTAC platform behind it, earns a second tumor. KIMMTRAK already funds the experiment. Second-quarter net product sales reached $115.9 million. Growth versus the year-ago quarter was 18%. The print is not an inflection so much as confirmation that an orphan T cell receptor franchise can keep compounding after the easy launch years, which is why the equity story now lives almost entirely in the cutaneous expansion rather than in another quarter of uveal share gains.
The binding near-term variable is TEBE-AM, the registrational Phase 3 study of tebentafusp in previously treated advanced cutaneous melanoma. Management timed topline overall survival as early as year-end, and a mid-September operating update said target enrollment of 540 patients is now achieved. That matters because no randomized trial has shown an overall survival gain in the post-checkpoint cutaneous setting. The company sizes the A02-positive second-line opportunity at up to 4000 patients across the United States and Europe. A hit would re-cut the addressable market well beyond the rare eye-cancer niche that currently carries the entire P&L. A miss would leave Immunocore as a high-quality but finite uveal franchise just as research spend on three late-stage programs is peaking.
What makes the setup investable rather than merely interesting is that the commercial engine is already covering the cost of the bet. Mid-year cash and marketable securities stood at $880.2 million. Combined research and selling expense in the quarter sat just under the product line. Net loss shrank to $0.8 million. First-half net income flipped to $12.2 million. Gross margin on KIMMTRAK is so wide that incremental volume drops almost straight through, which is why a mid-teens sales gain produced an almost-breakeven quarter even while three late-stage trials were enrolling. The rebate cash outflow of about $120 million due in the second half is a timing item, not a demand problem, but it does take a visible bite out of headline liquidity.
The Nasdaq ADS last changed hands near $36.13. The fifty-two week range runs from $27.56 to $40.72. Equity value sits near $1.9 billion. Enterprise value after cash and the 2030 converts sits closer to $1.4 billion, a low-single-digit multiple of trailing product sales. That multiple prices a durable orphan annuity and assigns little completed-work credit to TEBE-AM or to brenetafusp in first-line cutaneous disease. The strongest counterargument is clean. Uveal melanoma is a small pond, A02 restriction cuts the already-small cutaneous pool roughly in half, and cytokine-release monitoring keeps community adoption slower than a typical checkpoint launch. Whether the current multiple is cheap or merely fair depends on one survival curve that has not yet been unblinded.